Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
Amarin (NASDAQ: AMRN) has announced the immediate appointment of Michael Torok to its Board of Directors. Torok, who is the Co-Founder and Managing Director of investment firm JEC Capital Partners, brings financial expertise and board experience to the position.
Board Chairman Odysseas Kostas, MD, welcomed Torok, highlighting his financial background and alignment with shareholder interests. Torok expressed enthusiasm about working with fellow directors and senior management to maximize shareholder value, emphasizing the board's commitment to transparency.
Amarin (NASDAQ: AMRN) ha annunciato la nomina immediata di Michael Torok nel suo Consiglio di Amministrazione. Torok, co-fondatore e Direttore Generale della società di investimento JEC Capital Partners, porta con sé esperienza finanziaria e competenze nel settore.
Il Presidente del Consiglio, Odysseas Kostas, MD, ha dato il benvenuto a Torok, sottolineando il suo background finanziario e l'allineamento con gli interessi degli azionisti. Torok ha espresso entusiasmo nel lavorare con gli altri membri del consiglio e con la direzione per massimizzare il valore per gli azionisti, enfatizzando l'impegno del consiglio per la trasparenza.
Amarin (NASDAQ: AMRN) ha anunciado el nombramiento inmediato de Michael Torok en su Junta Directiva. Torok, cofundador y Director General de la firma de inversión JEC Capital Partners, aporta experiencia financiera y antecedentes en juntas a este puesto.
El Presidente de la Junta, Odysseas Kostas, MD, dio la bienvenida a Torok, destacando su experiencia financiera y su alineación con los intereses de los accionistas. Torok expresó su entusiasmo por trabajar con los demás directores y la alta dirección para maximizar el valor para los accionistas, enfatizando el compromiso de la junta con la transparencia.
Amarin (NASDAQ: AMRN)은 Michael Torok을 이사회의 새로운 이사로 즉시 임명했다고 발표했습니다. Torok은 투자 회사 JEC Capital Partners의 공동 창립자이자 관리 이사로서 재무 전문성과 이사회 경험을 이 자리에 제공합니다.
이사회 의장인 Odysseas Kostas, MD는 Torok을 환영하며 그의 재무 배경과 주주 이익과의 일치를 강조했습니다. Torok은 다른 이사들과 고위 경영진과 함께 주주 가치를 극대화하기 위해 일할 수 있게 되어 기쁘다고 밝혔으며, 이사회의 투명성에 대한 헌신을 강조했습니다.
Amarin (NASDAQ: AMRN) a annoncé la nomination immédiate de Michael Torok à son Conseil d'Administration. Torok, co-fondateur et Directeur Général de la société d'investissement JEC Capital Partners, apporte son expertise financière et son expérience au sein de conseils d'administration à ce poste.
Le Président du Conseil, Odysseas Kostas, MD, a accueilli Torok, mettant en avant son parcours financier et son alignement avec les intérêts des actionnaires. Torok a exprimé son enthousiasme à l'idée de travailler avec les autres administrateurs et la direction pour maximiser la valeur pour les actionnaires, en soulignant l'engagement du conseil envers la transparence.
Amarin (NASDAQ: AMRN) hat die sofortige Ernennung von Michael Torok in seinen Vorstand bekannt gegeben. Torok, Mitbegründer und Geschäftsführer der Investmentfirma JEC Capital Partners, bringt finanzielle Expertise und Erfahrung im Vorstand in diese Position ein.
Der Vorsitzende des Vorstands, Odysseas Kostas, MD, begrüßte Torok und hob seinen finanziellen Hintergrund sowie die Übereinstimmung mit den Interessen der Aktionäre hervor. Torok äußerte seine Begeisterung, mit den anderen Direktoren und dem oberen Management zusammenzuarbeiten, um den Aktionärswert zu maximieren, und betonte das Engagement des Vorstands für Transparenz.
- Appointment of experienced financial executive with board expertise
- Addition of shareholder-aligned director focused on maximizing value
- Enhanced board oversight with investment management expertise
- None.
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately.
“On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time,” said Odysseas Kostas, MD, Chairman of the Board.
“I am eager to join the board and begin working with fellow directors and the senior management team to deliver on our shared interest to maximize value,” said Michael Torok, Co-Founder and Managing Director of JEC Capital Partners. “I appreciate the Amarin board’s commitment to transparency and desire to work together for the interests of all shareholders.”
About Michael Torok
Mr. Torok currently serves as Co-Founder and Managing Director of JEC Capital Partners, LLC, an investment firm with offices in the United States and Germany. Beyond investing and portfolio management, Mr. Torok has extensive experience as a corporate director, having served on the boards of multiple public and private companies across various industries. He has contributed to audit, compensation, nominating and governance, strategic, and pricing committees, bringing expertise in capital allocation, shareholder return initiatives, mergers and acquisitions, and operational improvements.
Prior to co-founding JEC Capital Partners, Mr. Torok served as Chief Financial Officer of Integrated Dynamics Engineering, a global provider of OEM subsystems for semiconductor and medical precision tool makers, where he played a key role in its acquisition by Aalberts Industries. Earlier in his career, he held various positions at PricewaterhouseCoopers LLP, specializing in financial services.
Mr. Torok holds a B.S. in Accounting and Finance and an M.S. in Finance from Boston College.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
Investor.relations@amarincorp.com
FAQ
Who is the newest board member appointed to Amarin (AMRN)?
What experience does Michael Torok bring to Amarin's (AMRN) board?
When did Michael Torok join Amarin's (AMRN) board of directors?
What is Michael Torok's primary focus for Amarin (AMRN) as a new board member?
